Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system - PubMed

Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system - PubMed

Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system

Petra W C Lee 1, Angela C Bedard 2, Setareh Samimi 3, Vivienne K Beard 1, Quan Hong 2, James E J Bedard 1, Blake Gilks 4, David F Schaeffer 4, Robert Wolber 4, Janice S Kwon 5, Howard J Lim 6, Sophie Sun 2 6, Kasmintan A Schrader 2 7 8

Affiliations 

• PMID: 32700475
 
• DOI: 10.1002/cam4.3279

Free article

Abstract

Purpose: Referrals for Lynch syndrome (LS) assessment have traditionally been based on personal and family medical history. The introduction of universal screening practices has allowed for referrals based on immunohistochemistry tests for mismatch repair (MMR) protein expression. This study aims to characterize the effect of universal screening in a publicly funded healthcare system with comparison to patients referred by traditional criteria, from January 2012 to March 2017.

Methods: Patient files from the time of initiation of universal screening from 2012 to 2017 were reviewed. Patients were sorted into two groups: (a) universally screened and (b) referred by traditional methods. Mutation detection rates, analysis of traditional testing criteria met, and cascade carrier testing were evaluated.

Results: The mutation detection rate of the universal screening group was higher than the traditionally referred group (45/228 (19.7%) vs 50/390 (12.5%), P = .05), though each were able to identify unique patients. An analysis of testing criteria met by each patient showed that half of referred patients from the universal screening group could not meet any traditional testing criteria.

Conclusion: The implementation of universal screening in a publicly funded system will increase efficiency in detecting patients with LS. The resources available for genetic testing and counseling may be more limited in public systems, thus inclusion of secondary screening with BRAF and MLH1 promoter hypermethylation testing is key to further optimizing efficiency.

Keywords: DNA mismatch repair; Lynch syndrome; colorectal cancer; endometrial cancer; genetic testing; immunohistochemistry.

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

References

REFERENCES

1. 1. Vindigni SM, Kaz AM. Universal screening of colorectal cancers for Lynch syndrome: challenges and opportunities. Dig Dis Sci. 2016;61(4):969-976.
2. 1. Zhang T, Boswell EL, McCall SJ, Hsu DS. Mismatch repair gone awry: management of Lynch syndrome. Crit Rev Oncol Hematol. 2015;93(3):170-179.
3. 1. Kwon JS. Improving survival after endometrial cancer: the big picture. J Gynecol Oncol. 2015;26(3):227-231.
4. 1. Walsh S. The pathology of Lynch syndrome. Diagn Histopathol. 2015;21(4):161-164.
5. 1. Frolova AI, Babb SA, Zantow E, et al. Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. Gynecol Oncol. 2015;137(1):7-13.